Figure 3.
Figure 3. Mx1-cre induced homozygous Mof loss in adult mice results in dramatic hematopoietic failure. (A) Schematic for competitive transplant experiment with whole BM cells derived from adult Mx1-cre;Moff/f, Mx1-cre, and Moff/f mice and BM cells from a B6.SJL mouse. B6.SJL recipient mice were injected with fresh BM cells shortly after lethal irradiation. After 16 weeks, half the mice per genotype were injected with pIpC and 2 weeks after the fifth dose of pIpC, mice were euthanized and processed. The experiment was performed with 2 donors per genotype and 16 to 18 recipients per group. (B) Percent of CD45.2 live cells in PB of mice at time of euthanasia after pIpC treatment. Each dot represents a single mouse in the experiment. (C) Percent of CD45.2 live cells in BM of mice at time of euthansia after pIpC treatment. (D) Percent of CD45.2 live cells in spleen of mice at time of euthanasia after pIpC treatment. (E) Percentages of mature B cells (B220+), myeloid cells (GR1+/MAC1+), and T cells (CD3+) in live CD45.2+ BM cells as measured by FACS at time of euthanasia. (F) The total number of CD45.2+ mature B cells, myeloid cells, and T cells as measured by FACS at time of euthanasia. (G) Percentages of long-term HSCs (CD150+/CD48–) within the live CD45.2+ LSK BM population as measured by FACS at time of euthanasia. *P = .0006; **P = .0001; ****P < .000006. Error bars represent SD of mean.

Mx1-cre induced homozygous Mof loss in adult mice results in dramatic hematopoietic failure. (A) Schematic for competitive transplant experiment with whole BM cells derived from adult Mx1-cre;Moff/f, Mx1-cre, and Moff/f mice and BM cells from a B6.SJL mouse. B6.SJL recipient mice were injected with fresh BM cells shortly after lethal irradiation. After 16 weeks, half the mice per genotype were injected with pIpC and 2 weeks after the fifth dose of pIpC, mice were euthanized and processed. The experiment was performed with 2 donors per genotype and 16 to 18 recipients per group. (B) Percent of CD45.2 live cells in PB of mice at time of euthanasia after pIpC treatment. Each dot represents a single mouse in the experiment. (C) Percent of CD45.2 live cells in BM of mice at time of euthansia after pIpC treatment. (D) Percent of CD45.2 live cells in spleen of mice at time of euthanasia after pIpC treatment. (E) Percentages of mature B cells (B220+), myeloid cells (GR1+/MAC1+), and T cells (CD3+) in live CD45.2+ BM cells as measured by FACS at time of euthanasia. (F) The total number of CD45.2+ mature B cells, myeloid cells, and T cells as measured by FACS at time of euthanasia. (G) Percentages of long-term HSCs (CD150+/CD48) within the live CD45.2+ LSK BM population as measured by FACS at time of euthanasia. *P = .0006; **P = .0001; ****P < .000006. Error bars represent SD of mean.

Close Modal

or Create an Account

Close Modal
Close Modal